News Articles Tagged: RDEA3170

The Evolving Landscape of Gout Treatment: Insights into Verinurad (RDEA3170)

Explore how Verinurad (RDEA3170), a targeted URAT1 inhibitor, is shaping the future of gout and hyperuricemia treatment by focusing on uric acid excretion.

The Pharmaceutical Journey of Verinurad (RDEA3170): From Discovery to Clinical Trials

Trace the development path of Verinurad (RDEA3170), a crucial URAT1 inhibitor, highlighting its discovery, mechanism, and progression through clinical trials for gout and hyperuricemia.